78 2021 ESG Report Healthy workforce and communities Appendices Responsible supply chain Product impact Climate change Introduction Transparency U.S. lobbying expenditures $89,295 $135,139 $991,516 $636,000 2020 $131,656 $287,397 $1,279,300 $701,000 2021 BD associat es Public polic y consultants T rade associations Issue-based c oalitions Data represents calendar years Trade associations: AdvaMed, Healthcare Institute of New Jersey, California Life Sciences Association, North Carolina Biosciences Organization, Bio Nebraska Issue-based Coalitions: Diagnostic Test Working Group, Medical Device Competitiveness Coalition, Physicians Fee Schedule Pathology Payment Coalition, United for Medical Research, Corporate Friends of CDC, Inc. In addition to the work of our Public Affairs team, BD is able to expand our reach by leveraging state and federal public policy consultants, collaboratively engaging on issues that impact our industry through trade associations and advancing policy proposals focused on key priorities through advocacy coalitions. For calendar year 2021, the company spent approximately $2.4 million on salaries and expenses associated with lobbying in the United States. We file quarterly reports regarding our federal lobbying activities with the Office of the Clerk of the House of Representatives and the Secretary of the Senate. These reports are available by searching for “Becton Dickinson” as a “Registrant” on the U.S. Senate’s website, http://www.senate.gov/legislative/Public_Disclosure/ LDA_reports.htm Violations and compliance BD maintains robust processes for reporting violations of, and validating compliance with, law and company policy. Company personnel who believe they have witnessed illegal or unethical behavior relating to the company’s political activities are encouraged to discuss the matter with their manager, senior managers, Human Resources representatives, the Legal department or the Ethics and Compliance department. Actual or potential violations may be reported without risk of retaliation by using the confidential Ethics Helpline. Company policies and bylaws governing BD’s political activities may be subject to periodic compliance validation and/or internal audit review to determine the effectiveness of implementation and ongoing compliance with policy. Findings and mitigation strategies may be reviewed with appropriate stakeholders. Significant exceptions may be reported to the Corporate Governance and Nominating Committee. Enterprise risk management Our Enterprise Risk Management program is overseen by the SVP Chief Risk Officer. Operationally he reports to the Audit Committee of the Board, and administratively to the chief financial officer. The Audit Committee of the Board has responsibility to review BD’s guidelines and policies relating to enterprise risk assessment and management, including financial risk, and cybersecurity and data privacy risk exposures. In addition, the Corporate Governance and Nominating Committee oversees BD’s processes and practices relating to the management and oversight of various ESG matters. Further details about how the Board oversees risk can be found in our Pro xy Statement . Details of risk factors relevant to our business can be found in our annual report (10-K) and quarterly filings (10-Q). Details of how risks related to specific ESG issues are identified, assessed and managed, and how they integrate into the organization’s overall risk management program, can be found in the relevant sections of this report.